ArticleEJNMMI research2018
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- How to Integrate Surgery into the Multidisciplinary Treatment of Liver-Only Metastatic Colorectal Cancer.Cancers · 2026Review
- Multimodal imaging techniques in Yttrium-90 radioembolization for hepatocellular carcinoma: a modality-oriented clinical review.Frontiers in oncology · 2026Review
- Tumor Absorbed Dose Predicts Survival and Local Tumor Control in Colorectal Liver Metastases Treated with 90Y Radioembolization.Cardiovascular and interventional radiology · 2026Article
- Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy.Biomedicines · 2025Review
- An Evaluation of 90Y Bremsstrahlung SPECT Image Quality in the Presence of 99mTc: A Technical Perspective on Same-Day Radioembolization.Current oncology (Toronto, Ont.) · 2024Article
- The role of biomarkers and dosimetry parameters in overall and progression free survival prediction for patients treated with personalizedEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study.The British journal of radiology · 2024Article
- Review
- Trans-arterial Radioembolization Dosimetry in 2022.Cardiovascular and interventional radiology · 2022Review
- Article
- TCP post-radioembolization and TCP post-EBRT in HCC are similar and can be predicted using the in vitro radiosensitivity.EJNMMI research · 2022Article
- Concepts and methods for the dosimetry of radioembolisation of the liver with Y-90-loaded microspheres.Frontiers in nuclear medicine · 2022Review
- Article
- Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma.EJNMMI physics · 2021Article
- International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres.European journal of nuclear medicine and molecular imaging · 2021Article
- The joint use ofEJNMMI research · 2021Article
- Combined quality and dose-volume histograms for assessing the predictive value ofEJNMMI physics · 2020Article
- Selective internal radiation therapy of hepatic tumors: Morphologic and functional imaging for voxel-based computer-aided dosimetry.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Observational
- Comparative dosimetry betweenEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study.European journal of nuclear medicine and molecular imaging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this work was to confirm that post-selective internal radiation therapy (SIRT)
resultsFifty-seven evaluable mCRC lesions were included. The coefficient of correlation between Dmean and TLG-decrease was 0.82. Two lesion Dmean cutoffs of 39 Gy (sensitivity 80%, specificity 95%, predictive-positive-value 86% and negative-predictive-value 92%) and 60 Gy (sensitivity 70%, specificity 95%, predictive positive-value 96% and negative-predictive-value 63%) were defined to predict non-metabolic response and high-metabolic response respectively. Patients with all lesions Dmean> 39 Gy had a significantly longer OS (13 months) than patients with at least one lesion Dmean < 39 Gy (OS = 5 months) (p = 0.012;hazard-ratio, 2.6 (95% CI 0.98-7.00)).
conclusionsIn chemorefractory mCRC patients treated with SIRT, lesion Dmean determined on post-SIRT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.